Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)
Jump to navigation
Jump to search
Introduction
Study characteristics:
- 2,400 patients > 70 years of age with family history of Alzheimer's disease, asymptomatic at start of study
- randomized trial
Treatment
Results: (preliminary)
- increased risk of cardiovascular & cerebrovascular events in naproxen group compared with placebo
- no increase in cardiovascular or cerebrovascular events with celecoxib vs placebo
More general terms
References
- ↑ Prescriber's Letter 12(2): 2005 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210202&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ [No authors listed] Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006 Nov 17;1(7):e33 [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/17111043
Nissen SE. ADAPT: The Wrong Way to Stop a Clinical Trial. PLoS Clin Trials. 2006 Nov 17;1(7):e35 [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/17111045